⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JAGX News
Jaguar Health, Inc.
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
accessnewswire.com
JAGX
Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream
globenewswire.com
OSRH
SBC
KLXE
GRO
JAGX
XXII
OMEX
CLNN
FFAI
AEM
VOXR
MIGI
NVA
CIA
FUFU
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
globenewswire.com
OSRH
SBC
KLXE
GRO
JAGX
XXII
OMEX
CLNN
FFAI
AEM
VOXR
MIGI
NVA
CIA
FUFU
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
accessnewswire.com
JAGX
Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
accessnewswire.com
JAGX
Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to the Launch of Novel GLP-2 Analogues | DelveInsight
prnewswire.com
IRWD
ZPH
TAK
JAGX
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
accessnewswire.com
JAGX
In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial
accessnewswire.com
JAGX
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
accessnewswire.com
JAGX
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates
accessnewswire.com
JAGX